ストックスクリーナーアプリを入手
27.79
2.35%
-0.67
アフターアワーズ：
27.79
前日終値:
$28.46
開ける：
$28.37
24時間の取引高:
956.57K
Relative Volume:
0.76
時価総額：
$3.25B
収益：
$22.57M
当期純損益:
$-212.73M
株価収益率:
-15.40
EPS:
-1.8045
ネットキャッシュフロー:
$-142.19M
1週間 パフォーマンス:
-6.24%
1か月 パフォーマンス:
-18.00%
6か月 パフォーマンス:
-10.70%
1年 パフォーマンス:
+27.42%
1日の値動き範囲:
$27.31
$28.76
1週間の範囲:
$26.99
$31.29
52週間の値動き範囲:
$21.14
$42.20
Newamsterdam Pharma Company Nv Stock (NAMS) Company Profile
Compare NAMS vs VRTX, REGN, ARGX, RVMD, ONC
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
NAMS
Newamsterdam Pharma Company Nv
|
27.79 | 3.53B | 22.57M | -212.73M | -142.19M | -1.8045 |
VRTX
Vertex Pharmaceuticals Inc
|
477.10 | 121.57B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
762.63 | 69.95B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
853.82 | 55.61B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
187.53 | 39.98B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
316.01 | 33.81B | 5.76B | 514.49M | 1.10B | 4.4813 |
Newamsterdam Pharma Company Nv Stock (NAMS) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-03-18 | 開始されました | Truist | Buy |
| 2025-10-20 | 再開されました | H.C. Wainwright | Buy |
| 2025-08-25 | 開始されました | Wells Fargo | Overweight |
| 2025-07-17 | 開始されました | Goldman | Neutral |
| 2025-06-17 | 開始されました | Citigroup | Buy |
| 2025-06-10 | 開始されました | Stifel | Buy |
| 2025-06-04 | 開始されました | Cantor Fitzgerald | Overweight |
| 2024-12-30 | 開始されました | H.C. Wainwright | Buy |
| 2024-05-15 | 開始されました | TD Cowen | Buy |
| 2024-03-14 | 開始されました | Scotiabank | Sector Outperform |
| 2024-01-18 | 開始されました | Guggenheim | Buy |
| 2024-01-16 | 開始されました | Piper Sandler | Overweight |
| 2023-10-30 | 開始されました | RBC Capital Mkts | Outperform |
すべてを表示
Newamsterdam Pharma Company Nv (NAMS) 最新ニュース
NewAmsterdam Pharma Company NV (NAMS) Valuation: PE, PB & Fair Value Analysis - TradingKey
NAMS|NewAmsterdam Pharma Company NV|Price:30.190|Chg%:+0.550 - TradingKey
NewAmsterdam Pharma Company NV (NAMS) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
NewAmsterdam Pharma Company NV - TradingKey
NewAmsterdam Pharma Company NV (NAMS) Income Statement - TradingKey
TradingKey - TradingKey
NewAmsterdam Pharma says EU CHMP backs approval of Ubeslo, Evlarco cholesterol drugs - Bitget
NewAmsterdam Pharma Company NV (NAMS) Institutional Confidence - TradingKey
NewAmsterdam Pharma Company NV (NAMS) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
NewAmsterdam Pharma Company NV (NAMS) Cash Flow - TradingKey
NewAmsterdam Pharma Company NV (NAMS) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
NewAmsterdam Pharma: Obicetrapib Is More Than Another LDL-Lowering Pill - Seeking Alpha
NAMS|NewAmsterdam Pharma Company NV|Price:29.640|Chg%:-0.910 - TradingKey
NewAmsterdam says EU CHMP backs Ubeslo, Evlarco cholesterol drugs for approval - Bitget
NewAmsterdam Pharma (NAMS) Slides 2.98% as Biotech Sector Faces HeadwindsNews Sentiment - dars.gov.et
How EMA’s Positive CHMP Opinion on Ubeslo and Evlarco at NewAmsterdam Pharma (NAMS) Has Changed Its Investment Story - simplywall.st
NewAmsterdam and Menarini Receive Positive CHMP Opinion for Ubeslo and Evlarco - Intellectia AI
EQS-News: NewAmsterdam Pharma and Menarini Group Receive Positive CHMP Opinion Recommending Marketing Authorization for Ubeslo® (Obicetrapib Monotherapy) and Evlarco® (Obicetrapib Plus Ezetimibe Fixed-Dose Combination)boerse.de - boerse.de
NewAmsterdam Pharma and Menarini Group Receive Positive CHMP Opinion Recommending Marketing Authorization for Ubeslo® (Obicetrapib Monotherapy) and Evlarco® (Obicetrapib Plus Ezetimibe Fixed-Dose Combination) - recnews.it
Newamsterdam Pharma Company N.V. and Menarini Group Receives Positive CHMP Opinion Recommending Marketing Authorization for Ubeslo (Obicetrapib Monotherapy) and Evlarco (Obicetrapib Plus Ezetimibe Fixed-Dose Combination) - marketscreener.com
NewAmsterdam Pharma Wins EMA Backing for Obicetrapib Therapies - TipRanks
NewAmsterdam Pharma gets positive CHMP opinion for obicetrapib-based Ubeslo and Evlarco, EC decision due 2H26 - TradingView
NewAmsterdam Pharma and Menarini Group Receive Positive - GlobeNewswire
NewAmsterdam Pharma says EMA panel backs EU approval for Ubeslo, Evlarco cholesterol drugs - Bitget
NewAmsterdam Pharma Company (NAMS) Q1 2026 earnings summary - Quartr
NewAmsterdam Pharma Announces COO Transition and Advisory Role - TipRanks
NewAmsterdam Pharma's COO Douglas Kling to Leave for CEO Role at Another Clinical-Stage Biotech Company - Kalkine Media
Form 4 NewAmsterdam Pharma Co N.V. For: 22 July By Investing.com - Investing.com Nigeria
NewAmsterdam Pharma (NAMS) COO Douglas Kling to step down Aug 14 - Stock Titan
NewAmsterdam Pharma (NAMS) CAO trades 105000 shares under 10b5-1 plan - Stock Titan
NewAmsterdam Pharma Company N.V. Announces Resignation of Douglas Kling from Chief Operating Officer, Effective August 14, 2026 - marketscreener.com
Enterprise value to revenue forward of NewAmsterdam Pharma Company N.V. – NASDAQ:NAMS - TradingView
Enterprise value to revenue forward of NewAmsterdam Pharma Company N.V. – SWB:KH6 - TradingView
NewAmsterdam Pharma Company (NAMS) Citi Annual Global Healthcare Conference 2025 summary - Quartr
Jefferies reiterates NewAmsterdam Pharma stock rating ahead of data - Investing.com UK
Jefferies reiterates NewAmsterdam Pharma stock rating ahead of data By Investing.com - Investing.com Nigeria
Responsive Playbooks and the NAMS Inflection - Stock Traders Daily
NewAmsterdam Pharma publishes obicetrapib Alzheimer’s prevention research presentation - Bitget
Enterprise value to revenue forward of NewAmsterdam Pharma Company N.V. – MUN:KH6 - TradingView
Price-Driven Insight from (NAMSW) for Rule-Based Strategy - Stock Traders Daily
NewAmsterdam Pharma (NAMS) Drops 5.6% as Selling Pressure IntensifiesLarge Cap Trends - dars.gov.et
Price to sales forward of NewAmsterdam Pharma Company N.V. – NASDAQ:NAMS - TradingView
NewAmsterdam Pharma (NAMS) Dips Amidst Sector Rotation; Key Support in FocusFundamental Weighted - dars.gov.et
NewAmsterdam Pharma to Present Obicetrapib Alzheimer’s Data - t.co
NewAmsterdam Pharma (NAMS) Alzheimer’s Data Push Puts Fair Value Back In Focus - Sahm
NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Sahm
NAMSNewAmsterdam Pharma Company NV Latest SEC Filings - Finviz
(NAMSW) Price Dynamics and Execution-Aware Positioning - Stock Traders Daily
NewAmsterdam Pharma Announces Upcoming Presentations at the Alzheimer's Association International Conference (AAIC) 2026 - marketscreener.com
NewAmsterdam Pharma Company N.V. - TradingView
Price to sales forward of NewAmsterdam Pharma Company N.V. – BOATS:NAMSW - TradingView
Newamsterdam Pharma Company Nv (NAMS) 財務データ
収益
当期純利益
現金流量
EPS
Newamsterdam Pharma Company Nv (NAMS) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Kooij Louise Frederika | Chief Accounting Officer |
Jul 20 '26 |
Sale |
30.34 |
105,000 |
3,185,656 |
24,353 |
| Kooij Louise Frederika | Chief Accounting Officer |
Jun 22 '26 |
Option Exercise |
11.28 |
40,000 |
451,000 |
64,353 |
| Kooij Louise Frederika | Chief Accounting Officer |
Jun 22 '26 |
Sale |
30.20 |
40,000 |
1,208,159 |
24,353 |
| Kooij Louise Frederika | Chief Accounting Officer |
May 26 '26 |
Option Exercise |
10.07 |
65,000 |
654,500 |
89,353 |
| Kooij Louise Frederika | Chief Accounting Officer |
May 26 '26 |
Sale |
35.69 |
65,000 |
2,319,850 |
24,353 |
2.44%
0.02%
大文字化:
|
ボリューム (24 時間):